Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
about
Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotypeDiversity and functional consequences of germline and somatic PTPN11 mutations in human disease.Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding proteinSalicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cellsPTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effectsGermline KRAS mutations cause Noonan syndromeProtein tyrosine phosphatases in the JAK/STAT pathwayRas oncogenes: split personalitiesPI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrumMutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Noonan syndrome: clinical aspects and molecular pathogenesis.SHP2E76K mutant promotes lung tumorigenesis in transgenic micep38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytesIdentification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).Protein tyrosine phosphatases as potential therapeutic targets.A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanismsSHP2 is a target of the immunosuppressant tautomycetin.Noonan syndrome and clinically related disorders.Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorderTargeting protein tyrosine phosphatases for anticancer drug discovery.Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burstGenetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76KA critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.Molecular targets for the treatment of juvenile myelomonocytic leukemia.SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responsesMutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.Structure-based kinetic models of modular signaling protein function: focus on Shp2.Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling.LST1/A is a myeloid leukocyte-specific transmembrane adaptor protein recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to the plasma membrane.Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
P2860
Q24293473-13C925CE-7843-4935-848D-2F74BD937202Q24540529-6B34C78C-8EF8-4A8F-B486-D38868777DAAQ24670487-91162F14-D128-4B51-85BC-E415E38A288EQ27659942-22B3B13E-AEB4-4BA8-97C7-A0F54DF32C4DQ28281520-47B3E7FE-506A-4189-9D5A-F10DF843C16EQ28288812-8F8F273B-23F1-4D7C-AFCA-4D7833301193Q28297024-F9BC9FC9-3A11-4F83-981F-1498DC5D0C96Q28646447-CA3CDCC9-9C57-42F9-95FA-FD4DD0CEA15CQ29615405-2355C611-DE3F-464D-B736-DC8BFAEC697CQ33556937-ED80E3DC-0D61-40A2-9004-1DDA3A8A4AE8Q33637874-31C500AC-47FF-4AB7-9AAC-EAEB6E026D69Q33722741-1C1EFDCC-72E2-4387-9AD4-0E62D165D7E5Q33774488-ED781EE3-EA99-4007-BC87-46386F654160Q33806161-01BF7281-E713-4E16-99AF-AB1150F12E10Q34009953-42C58A83-C19C-40A7-996D-5C59CF3DC485Q34123342-4B505C86-6AC5-4BB1-B36D-74293336B4ABQ34155125-A95E583D-05AE-40F2-AB04-2D32ECEF9165Q34295063-BFA11838-AD3C-4134-B9C5-F79773E0828EQ34310556-E75F51B2-766F-4773-8DDC-812E165596CFQ34399676-657EE32D-6114-466C-8E5E-08212AF2F012Q34440570-6B97F4D4-1E29-4976-A001-F1A3ED5021E2Q34554631-2A22DB29-7A5D-42ED-8777-2A87A960C07CQ34678373-F8B48085-C2EA-4035-8D24-05A23ECD0BAFQ34722748-065379B4-7335-420B-B105-D5226265F920Q34789961-D8843805-55E6-4F59-8D38-CB6F574974CFQ35080194-4C76D095-087C-4BA6-8F48-783046601C3CQ35133448-24EED522-9C47-459F-AA9D-09E8A6EB8A4EQ35164251-A36EB734-546C-4C35-BD76-914944F4A071Q35237519-199E2674-7A59-417F-93FA-264CFBD04B98Q35579349-3AA2A2CC-5574-44F3-AAB1-B9A65292109DQ35615838-5667CD82-4E43-43F3-B68E-01A39A2C964FQ35616065-95391AC1-527D-4352-B871-84692C23DBF0Q35630243-D3CAA051-C3E3-47BA-A3E9-E8D303162664Q35685296-A9EE99FE-59B5-473B-987E-97B1B61C25A2Q35781235-78D0EF9E-CD56-43A0-A472-2117A79FB8E4Q35847802-D1004797-8A7D-4505-AAA2-FE43CE4B5742Q35847884-CFF18D5E-3CF4-4CF8-BA73-09DB5F4E8F16Q35921878-73034FA0-BF7F-4771-9441-88362C92B8B9Q36080432-4E6BD789-15A9-4431-8441-C4DF2020DEFEQ36094712-3D93F657-BBE1-4741-8D0F-A77F880AC194
P2860
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@ast
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@en
type
label
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@ast
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@en
prefLabel
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@ast
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@en
P2093
P2860
P1433
P1476
Human somatic PTPN11 mutations ...... age colony-stimulating factor.
@en
P2093
Cara S Voorhorst
Melissa B Leedy
Menggang Yu
Rebecca J Chan
Reuben Kapur
Veerendra Munugalavadla
P2860
P304
P356
10.1182/BLOOD-2004-10-4002
P407
P577
2005-01-11T00:00:00Z